Skip to contentS
Sunshine Biopharma Inc.
S
SBFMSunshine Biopharma Inc. Q1 2023 · 10-Q
Revenue$4.89M$4.89M+3,890.4% vs Q1 2022 Net Income-$1.70M-$1.70MN/M vs Q1 2022 EPS Diluted-$7.73-$7.73N/M vs Q1 2022 Gross Profit$1,828,122+2,811.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
Operating Cash Flow-$1,850,106N/M Margins · derivedGross margin37.4%−13.9 pt vs Q1 2022
Operating margin-37.4%+960.1 pt vs Q1 2022
Net margin-34.8%+973.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end